Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.79 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658661 | 1.00 | OPRM1 (0.79) | OPRM1OPRK1OPRD1 | |
| SCHEMBL11401193 | 0.87 | OPRM1 (0.69) | OPRM1OPRK1OPRD1 | |
| SCHEMBL7623588 | 0.87 | OPRM1 (0.66) | OPRM1OPRK1OPRD1 | |
| SCHEMBL7623592 | 0.87 | OPRM1 (0.66) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5795228 | 0.86 | OPRM1 (0.68) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5765577 | 0.86 | OPRM1 (0.68) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6486106 | 0.86 | OPRM1 (0.79) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6656032 | 0.86 | OPRM1 (0.79) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5762379 | 0.83 | OPRM1 (1.00) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5762377 | 0.83 | OPRM1 (1.00) | OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
| US-6441000-B1 | DISEASES MEDIATED BY OPIATE RECEPTORS | PFIZER INC | 2002-08-27 | — | — | US | disclosed |
| EP-1077940-A1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-1055668-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | OPRM1 409/4885OPRK1 144/4885OPRD1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.